Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

A federal rule to limit coal miners’ exposure to dangerous silica dust — which was set to go into effect next week after ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

A new research paper was published in Volume 17, Issue 7, of Aging (Aging-US) on July 3, 2025, titled "Frailty associates ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...